Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn
GLP-1 products such as Ozempic and Mounjaro spread but many in poorer countries struggle to get basic diabetes treatment The gold rush into GLP-1 weight-loss drugs risks diverting pharmaceutical…
The Guardian
Full text, translation and AI summary — after signing in
- The full article in your language
- AI summary and translation from the original
- The same account works in the Suviy app
Related coverage
Comments
Sign in to join the conversation. Sign in
No comments yet.